Stocks discussed on the in-depth session of Jim Cramer’s Mad Money TV Program, Wednesday, December 21.
Is it too late to participate in the rally? Cramer doesn’t think so. “If you want to understand how this market has been able to run so much since the election, you have to stop thinking of the stock market as some kind of unified whole, and start viewing it as a market of stocks,” he said.
The stocks that are leading the Dow to hit 20,000 are less vulnerable and are justified to be at the current levels, in Cramer’s opinion. Most of the gains in the Dow are from stocks that are up more than 10% since the election, and don’t have a lot of overhead supply.
The stocks always had sellers and profit taking, but that rhetoric has changed since the election. “The biggest winners here are a host of stocks that simply don’t have a lot of flippers; there is not much profit-taking because at least so far there isn’t much profit to take,” he said. Some of those names are American Express (NYSE:AXP), Travelers (NYSE:TRV), UnitedHealth (NYSE:UNH), Boeing (NYSE:BA), Disney (NYSE:DIS), Verizon (NYSE:VZ), Chevron (NYSE:CVX), Caterpillar (NYSE:CAT), Goldman Sachs (NYSE:GS) and JP Morgan (NYSE:JPM).
Best Gold Stocks To Invest In Right Now: InterCloud Systems, Inc(ICLD)
- [By Monica Gerson]
InterCloud Systems Inc (NASDAQ: ICLD) is expected to post a quarterly loss at $0.14 per share on revenue of $24.00 million.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
Best Gold Stocks To Invest In Right Now: ARIAD Pharmaceuticals Inc.(ARIA)
- [By Lisa Levin]
Healthcare shares gained around 0.73 percent in trading on Monday. Meanwhile, top gainers in the sector included Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and VCA Inc (NASDAQ: WOOF).
Best Gold Stocks To Invest In Right Now: Amgen Inc.(AMGN)
- [By ]
For example, if you buy 100 shares of theNasdaq100ETF(NYSE: QQQ), you’re theoretically buying 11.9 shares of Apple (NASDAQ: AAPL)… 7.7 shares of Facebook (NASDAQ: FB)… 1.8 shares ofAmgen(NASDAQ: AMGN)… 2.6 shares of Comcast (NASDAQ: CMCSA)… and even smaller amounts of about 95 different companies.
- [By Jon C. Ogg]
In September of 2016, Amgen Inc. (NASDAQ: AMGN) announced that the FDA had approved its Amjevita as a biosimilar to Humira for multiple inflammatory diseases that included RA and several other related inflammatory diseases.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.46 million shares from the previous level of 9.49 million. Shares were last seen at $171.94, in a 52-week trading range of $152.16 to $201.23.
- [By Todd Campbell]
When a brand new class of cholesterol-lowering drugs called PCSK9 inhibitors won Food and Drug Administration (FDA) approval in 2015, it was heralded as the biggest advance in battling heart disease since the invention of statins. The launch of PCSK9 inhibitors was accompanied by billion-dollar-plus predictions for sales. However, revenue has fallen far shy of blockbuster status, leaving drugmakers Amgen Inc. (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), and Sanofi SA (NYSE:SNY) in the lurch.
- [By Joseph Griffin]
Field & Main Bank grew its stake in shares of Amgen (NASDAQ:AMGN) by 9.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,153 shares of the medical research company’s stock after buying an additional 345 shares during the quarter. Field & Main Bank’s holdings in Amgen were worth $708,000 at the end of the most recent quarter.